SCHEMBL836823

SCHEMBL836823

N#CCc1cc(Cl)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.50
MAPT P10636 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 2/20 0.38
IDO1 P14902 2/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.38
HIF1A Q16665 2/20 0.38
SLC22A1 O15245 1/20 0.38
USP2 O75604 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CYP3A4 P08684 1/20 0.38
HSPD1 P10809 1/20 0.38
HSPA5 P11021 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
CASP1 P29466 1/20 0.38
BLM P54132 1/20 0.38
HSPE1 P61604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444029 0.86 CYP2A6 (0.49) CYP2A6MAPTKMT2AIDO1CYP3A4
SCHEMBL30317077 0.86 CYP2A6 (0.49) CYP2A6MAPTKMT2AIDO1CYP3A4
SCHEMBL11339655 0.83 CYP2A6 (0.53) CYP2A6MAPTMEN1KMT2ALMNA
SCHEMBL30453664 0.81 CYP2A6 (0.51) CYP2A6MAPTMEN1KMT2ALMNA
SCHEMBL29618975 0.81 PSEN1 (0.40) CYP2A6IDO1MPOPSEN1PSEN2
SCHEMBL2581205 0.81 CYP2A6 (0.51) CYP2A6MAPTMEN1KMT2ALMNA
SCHEMBL1020440 0.81 PSEN1 (0.40) CYP2A6IDO1MPOPSEN1PSEN2
SCHEMBL11150187 0.78 CYP2A6 (0.49) CYP2A6MAPTMEN1KMT2ALMNA
SCHEMBL9543269 0.78 ESR2 (0.45) ALDH1A1ESR1ESR2
SCHEMBL138085 0.78 CSNK2A1 (0.49) CYP2A6HPGDALDH1A1CSNK2A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283701-B Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide 中国科学院上海药物研究所 2025-04-22 CN disclosed
CN-118047784-A Small molecule compound with substituted phenyl spiro [ indoline-3, 3' -pyrrolidine ] structure 中国科学院上海药物研究所 2024-05-17 CN disclosed
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2024-02-01 US disclosed
CN-117120416-A Small molecule compound with substituted phenyl spiro [ indoline-3, 3' -pyrrolidine ] structure 中国科学院上海药物研究所 2023-11-24 CN disclosed
EP-4242202-A1 BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) 2023-09-13 EP disclosed
EP-4217065-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2023-08-02 EP disclosed
CN-116368112-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2023-06-30 CN disclosed
CN-116283701-A Compounds having the structure 4- (substituted aminomethyl) -5-neopentyl-N-substituted pyrrolidine-2-carboxamide 中国科学院上海药物研究所 2023-06-23 CN disclosed
EP-3362445-B1 OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2023-01-25 EP disclosed
EP-3362445-B1 OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2023-01-25 EP disclosed
US-7629358-B2 Compounds useful for the treatment of diseases PFIZER INC (US) 2009-12-08 US disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
US-20090088425-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040288-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed
CN-1942432-A Phenylethanolamine derivatives as beta-2 agonists PFIZER LTD (US) 2007-04-04 CN disclosed
EP-1727789-A2 PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS Pfizer Limited (GB) 2006-12-06 EP disclosed
US-20050234097-A1 Compounds useful for the treatment of diseases PFIZER INC 2005-10-20 US disclosed
WO-2005090287-A2 PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS PFIZER LIMITED (GB) 2005-09-29 WO disclosed
US-4369322-A WITH CYANOGEN CHLORIDE DEGUSSA AG (DE) 1983-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234097-A1 Compounds useful for the treatment of diseases LTC4S, CYP11B2, CYP11B1 CYP2A6 150/4885MAPT 2364/4885MEN1 1255/4885
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 CYP2A6 3931/4885MAPT 1408/4885MEN1 3564/4885
US-20090088425-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R CYP2A6 470/4885MAPT 3375/4885MEN1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.